{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Morphiex Biotherapeutics (\"Morphiex\") located in Boston, MA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/05/15/2018-10238.html","cfr_references":[],"citation":"83 FR 22501","comment_url":null,"comments_close_on":"2018-05-30","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before May 30, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-10238","effective_on":null,"end_page":22501,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/05/15/2018-10238.xml","html_url":"https://www.federalregister.gov/documents/2018/05/15/2018-10238/prospective-grant-of-an-exclusive-patent-license-use-of-the-cd47-phosphorodiamidate-morpholino","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-10238?publication_date=2018-05-15","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-05-15/2018-10238/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":240,"last_updated":"2026-07-27 18:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-05-15/pdf/2018-10238.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-10238.pdf?1526301921","publication_date":"2018-05-15","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/05/15/2018-10238.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T19:53:58Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":22501,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Use of the CD47 Phosphorodiamidate Morpholino Oligomers for the Treatment, Prevention, and Diagnosis of Hematological Cancers","toc_doc":"Use of CD47 Phosphorodiamidate Morpholino Oligomers for Treatment, Prevention, and Diagnosis of Hematological Cancers","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}